Bruker宣布收购MERLIN

red

Bruker Announces Acquisition of MERLIN to Add Selected Antibiotic Resistance and Susceptibility Testing to its MALDI Biotyper® Microbial Identification Platform

BREMEN, Germany – September 26, 2017 - Bruker today announced the closing of its acquisition of MERLIN Diagnostika GmbH, located near Bonn, Germany.  MERLIN has in-depth expertise in products, services and consulting in the fields of antibiotic resistance testing (ART) and antibiotic susceptibility testing (AST).  MERLIN’s technology and product portfolio for human and veterinary antibiotic resistance and specialty susceptibility testing further expands Bruker′s microbiology business, which is based on rapid, broad-based microbial identification using Bruker’s market-leading MALDI Biotyper (MBT) platform for proteomic fingerprinting.  Financial details were not disclosed.


       The principle of the MERLIN MICRONAUT™ system for specialty susceptibility testing is the phenotypic detection of microbial growth inhibition in the presence of antibiotics. Its microdilution procedure is a standardized, globally accepted reference method for the determination of minimal inhibitory concentrations (MICs). Standard and special AST plates are available for in-vitro diagnostic use according to the EU directive EC/98/79 for a wide spectrum of clinically important microorganisms.  MERLIN’s focus is on the detection of major resistance phenotypes, i.e. MRSA, VRE, MBL, ESBL, KPC, AMP-C, and OXA-48. In addition, MERLIN has the ability to customize antibiograms for more than 200 antibiotics.  Due to this flexibility, the MICRONAUT system enables laboratories to adjust their testing profiles to the rapid spread of certain new resistances. MICRONAUT software for identification and susceptibility testing includes an expert plausibility check, and has for several years already offered an interface to Bruker′s MALDI Biotyper.


      MERLIN is a member of the German Diagnostic Industry Association (VDGH) and the Paul-Ehrlich-Society for Chemotherapy (www.p-e-g.org), and MERLIN is involved in various studies related to antibiotic resistance, e.g. the monitoring of drug resistance among clinically relevant pathogens in Germany and central Europe.  For such multicenter studies involving human and veterinary medicine, MERLIN offers the design and production of dedicated MIC study plates, as well as scientific consulting and support.  MERLIN acts as a reference laboratory for annual inter-laboratory tests by the INSTAND organization (www.instand-ev.de) for quality assurance in microbiology.


     MERLIN will continue to serve all existing collaboration and distribution partners, as well as all OEM customers and end customers after the acquisition.


      Dr. Esther Pfeil, Managing Director of MERLIN Diagnostika GmbH, commented: “We are very pleased to be part of Bruker′s microbiology business now, as we have been collaborating with Bruker already for several years.  Our product and service offerings in the field of antibiotic susceptibility testing (AST) complement the MALDI Biotyper system for fast and efficient microbial identification.  With our proven expertise in the field of AST, we aim to accelerate further assay additions to the MBT-STAR™ consumables portfolio for selected, rapid antibiotic resistance and susceptibility testing on the MALDI Biotyper.”


      Dr. Johann-Wolfgang Wittke, Managing Director of the Medical Laboratory Bremen (Germany), said: “Our laboratory has been working with Bruker′s MALDI Biotyper for microbial identification and the MICRONAUT system from MERLIN for many years.  The MICRONAUT microdilution approach with the determination of true minimal inhibitory concentrations has leading analytical performance and reliability.  We use MERLIN’s custom-tailored microtiter plates to answer different microbiological questions, or for the detection of resistance mechanisms.  This flexibility is unmatched in the market, and I am looking forward to further integration, synergies and reduction of hands-on time.”


     Dr. Wolfgang Pusch, Executive Vice President for Microbiology & Diagnostics at Bruker Daltonics, added: “MERLIN adds expertise and an impressive portfolio of flexible specialty products for antibiotic susceptibility testing to Bruker’s clinical and applied microbiology business.  Over time, we expect that MERLIN will further expand our selected, high-value ART and AST assay portfolio for the MALDI Biotyper.”




     Bruker宣布收购MERLIN，为其MALDIBiotyper®微生物识别平台添加选定的抗生素耐药性和易感性检测

     BREMEN，德国 - 2017年9月26日 - Bruker今天宣布收购位于德国波恩附近的MERLIN Diagnostika GmbH。 MERLIN在抗生素抗性测试（ART）和抗生素敏感性测试（AST）领域的产品，服务和咨询方面具有深入的专业知识。 MERLIN针对人类和兽医抗生素耐药性和特异性敏感性测试的技术和产品组合进一步扩大了Bruker的微生物学业务，该业务基于使用Bruker市场领先的MALDI Biotyper（MBT）蛋白质指纹图谱的快速，广泛的微生物鉴定。财务细节未披露。

用于特异性敏感性测试的MERLIN MICRONAUT™系统的原理是在抗生素存在下微生物生长抑制的表型检测。其微量稀释程序是用于确定最小抑制浓度（MIC）的标准化，全球公认的参考方法。标准和特殊的AST平板可用于体外诊断用途，根据欧盟指令EC / 98/79针对广泛的临床重要微生物。 MERLIN的重点是检测主要的抗性表型，即MRSA，VRE，MBL，ESBL，KPC，AMP-C和OXA-48。此外，MERLIN能够为200多种抗生素定制抗生素。由于这种灵活性，MICRONAUT系统使实验室能够将其测试配置文件调整为快速扩展某些新的电阻。用于识别和敏感性测试的MICRONAUT软件包括专家合理性检查，并且已有几年已经提供了与Bruker的MALDI Biotyper接口。

MERLIN是德国诊断行业协会（VDGH）和Paul-Ehrlich化学疗法协会（www.p-e-g.org）的成员，MERLIN参与了与抗生素抗药性有关的各种研究，例如，监测德国和中欧临床相关病原体的耐药性。对于涉及人类和兽医学的多中心研究，MERLIN提供设计和生产专用MIC研究板，以及科学咨询和支持。美林作为微生物学质量保证的INSTAND组织（www.instand-ev.de）进行年度实验室间检测的参考实验室。

收购后，MERLIN将继续为所有现有的合作和分销合作伙伴以及所有OEM客户和最终客户提供服务。

MERLIN Diagnostika有限公司董事总经理Esther Pfeil博士评论说：“我们非常高兴成为Bruker微生物业务的一部分，因为我们已经与Bruker合作了好几年了。我们在抗生素敏感性测试（AST）领域的产品和服务提供了MALDI Biotyper系统，用于快速有效的微生物鉴定。凭借我们在AST领域的专业知识，我们的目标是进一步加快MBT-STAR™消耗品组合的测定，为MALDI Biotyper选择快速的抗生素耐药性和敏感性测试。

医学实验室不来梅（德国）董事总经理Johann-Wolfgang Wittke博士说：“我们的实验室已经与Bruker的MALDI Biotyper合作进行微生物鉴定，并与MERLIN多年的MICRONAUT系统合作。 MICRONAUT微量稀释方法具有真正的最小抑制浓度的测定，具有领先的分析性能和可靠性。我们使用MERLIN定制的微量滴定板来回答不同的微生物学问题，或用于检测抗药性机制。这种灵活性在市场上是无与伦比的，我期待着进一步整合，协同效应和减少实践时间。“

Bruker Daltonics微生物和诊断执行副总裁Wolfgang Pusch博士补充说：“MERLIN向Bruker的临床和应用微生物学业务增加了专业知识和令人印象深刻的抗生素敏感性测试灵活特性产品组合。随着时间的推移，我们预计MERLIN将进一步扩大我们为MALDI Biotyper选择的高价值ART和AST测定组合。“